Elite Pharmaceuticals Q1 Earnings Call Highlights

Elite Pharmaceuticals (OTCMKTS:ELTP) reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.

The quarter ended June 30, 2026, and Elite’s fiscal year ends March 31. Ward said comparisons with the prior-year quarter require context because the June 2025 period was the company’s strongest quarter to date, benefiting from the early stages of the generic lisdexamfetamine market, the generic version of Vyvanse.

“Revenues for the quarter were $32.4 million and operating profits were $7.5 million, both in line with the previous three quarters, both solid and steady,” Ward said.

Generic Market Pricing and Product Mix

Ward said Elite launched generic lisdexamfetamine in early 2025, entering a market that initially had relatively high prices but also drew more than 10 competing companies. As competition increased, prices declined before the market reached what he characterized as a more stable equilibrium.

According to Ward, Elite has maintained and increased its market share in lisdexamfetamine while prices, volumes and operations have stabilized. He said the company is now an established supplier of generic Vyvanse, similar to its longstanding position in generic Adderall products.

Chief Executive Officer Nasrat Hakim said overall volume increased 14.75% year over year during the quarter. He said lisdexamfetamine volume rose 10%, while market share increased 10.2% despite the price normalization following the initial generic launch.

Hakim said Elite’s four largest products—lisdexamfetamine, mixed amphetamine immediate-release, amphetamine extended-release and naltrexone—have gained market share while maintaining prices. Sales of legacy products including isradipine, trimipramine, trandolapril and phentermine were in line with previous years, he said.

Ward also addressed higher cost of goods sold, saying volume growth contributes to higher costs and that the sales mix has changed. Naltrexone, which Elite was not selling in the comparable prior-year period, uses an expensive active ingredient and has added to cost of goods sold, he said.

Elite’s largest customer accounted for 60% of revenue, compared with 51% a year earlier. Ward said the generic-drug market is broadly concentrated among a small number of large wholesalers, but he attributed lisdexamfetamine price changes to supply, demand and industry competition rather than customer concentration or price concessions from a particular customer.

Cash Flow, Liquidity and Warrants

Cash provided by operations was $10.1 million in the quarter, compared with $14.8 million in the year-earlier period. Ward said the prior-year cash flow figure reflected an extraordinary quarter, while the latest result exceeded cash flow generated in each of the final three quarters of fiscal 2026.

Cash rose to $38.9 million as of June 30 from $29.8 million at the beginning of the fiscal year. Ward said the company intends to focus its liquidity on new products, product-line expansion, facility improvements and capacity for increased production.

Working capital was $84.1 million at quarter-end, down from $94.7 million at the start of the year. Ward said the decline was primarily an accounting classification issue: approximately $17 million in warrant derivative liabilities moved from long-term to current liabilities because the warrants expire in April 2027.

Ward said the warrants may be exercised for about $12 million in cash, exercised on a cashless basis for fewer than 79 million shares depending on Elite’s share price at the time, or expire unexercised. He said the company is discussing the alternatives with Hakim, who holds the warrants, and expects a resolution before the April 2027 expiration.

Pipeline and Manufacturing Plans

Research and development expense was $2 million, compared with $1.7 million in the prior-year quarter. During the period, Elite launched methadone, filed both an NDA and an ANDA, and completed a successful pivotal bioequivalence study, Ward said. The company launched buprenorphine shortly after quarter-end.

Hakim said Elite reported a successful bioequivalence study for an undisclosed anticonvulsant product, whose branded equivalent has annual sales of $840 million according to IQVIA. Elite is preparing its FDA filing for the product, he said.

The company also filed an undisclosed anticoagulant product in June. Hakim said IQVIA reports $26 billion in sales for the branded product, which is not yet off patent. Elite is negotiating with the brand company over patents and potential market entry, and Hakim said his current expectation is for a 2028 launch.

Elite’s generic oxycodone extended-release product remains under FDA review. Hakim said the company also has authorization from Purdue to launch its RCR product by August 2027, but first must address an FDA question involving abuse deterrence. He said the company has begun working with consultants and internal staff on that issue.

Although Elite is currently operating one manufacturing shift, Hakim said the company is evaluating expansion into an adjacent warehouse to accommodate products in development. He said converting and qualifying the space and equipment for pharmaceutical manufacturing would take roughly two years.

Uplisting, M and Tariff Discussion

Hakim said Elite continues to evaluate a potential buyout and Nasdaq uplisting, seeking the alternative that provides the greatest shareholder value. The company is extending its agreement with its current adviser by six months while it continues to pursue potential transactions.

Regardless of a merger or acquisition, Hakim said Elite intends to move to Nasdaq. He said he did not expect an uplisting to occur before the company’s next call in November, but estimated that it could be completed or nearing completion by the following call in February.

Hakim also discussed proposed U.S. tariffs on imported generic drugs, saying no such tariffs are currently in place. He said proposals under discussion could impose 100% tariffs beginning in August 2028 and potentially increase them to 200% a year later. If enacted on finished products, he said the measures could improve Elite’s competitive position against overseas manufacturers and potentially make the company more attractive to foreign firms seeking U.S. manufacturing capacity.

About Elite Pharmaceuticals (OTCMKTS:ELTP)

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Source MarketBeat